In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.
Rena Goins
Advertisement
Rena Goins is executive director of global trade at Regeneron.
Articles by Rena Goins
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
When Drug Pricing Collides With Politics
2
How CMS’ Final Negotiation Rule Treats New Drug Formulations
3
The End of the Traditional Launch: How JCA, HTA Evolution and Pricing Pressures Are Driving Continuous Evidence Generation
4
Idle US Capacity Could Anchor Generic Drug Reshoring, APIIC Says
5